Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

Dr. McKay, Assistant Professor of Medicine, UCSD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study investigating pembrolizumab + axitinib or sunitinib in 1st line clear cell renal cell cancer (RCC) patients

Tags: ASCO Conference CoverageRenal Cell Carcinomca (RCC)

Published: 06 July 2020

Recent Videos

video

Petros Grivas, MD, PhD, offers perspective on the JAVELIN Bladder 100 trial updated at ESMO 2020

Dr. Grivas, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, University of Washington School of Medicine, Clinical ...

video

Petros Grivas, MD, PhD, summarizes the clinical progress made in prostate cancer from ESMO 2020

Dr. Grivas, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, University of Washington School of Medicine, Clinical ...

video

Alexander Stratigos, MD, PhD, speculates on next steps in the development of cemiplimab in BCC

Dr. Stratigos, Director, Dermato-Oncology Center and Melanoma Unit Andreas Sygros Hospital, Professor of Dermatology, Department of Dermatology-Venereology, University of Athens ...

video

Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC

Dr. Albigès, Head, Genitourinary Unit, Gustave Roussy Institute, considers whether certain patient subtypes are more likely to respond when administering ...

video

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

video

Laurence Albigès, MD, PhD, regarding the potential challenges when combining checkpoint inhibitors

Dr. Albigès, Head, Genitourinary Unit, Gustave Roussy Institute, considers the potential challenges and/or adverse events which physicians should be aware ...

video

Aditya Bardia, MD, MPH, considers the practice-changing potential of the ASCENT study from ESMO 2020

Dr. Bardia, Assistant Professor of Medicine, Harvard Medical School, Attending Physician, Medical Oncology, Massachusetts General Hospital, speculates on whether the ...

video

Petros Grivas, MD, PhD, discusses the COVID-19 and Cancer Consortium (CCC19) from ESMO 2020

Dr. Grivas, Physician, Seattle Cancer Care Alliance, Associate Professor, Division of Medical Oncology, University of Washington School of Medicine, Clinical ...

video

Alexander Stratigos, MD, PhD, on the latest data investigating the use of cemiplimab in BCC

Dr. Stratigos, Director, Dermato-Oncology Center and Melanoma Unit Andreas Sygros Hospital, Professor of Dermatology, Department of Dermatology-Venereology, University of Athens ...

video

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer ...

Related Videos

video-image

Laurence Albigès, MD, PhD, shares outcomes & updates from the CheckMate 214 study in advanced RCC

video-image

Laurence Albigès, MD, PhD, regarding the potential challenges when combining checkpoint inhibitors

video-image

Jaffer Ajani, MD, provides opinion on the role of I-O in treatment of esophageal & gastric cancers

video-image

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

video-image

Alexander Stratigos, MD, PhD, considers the effectiveness of hedgehog inhibitors in BCC

video-image

Laurence Albigès, MD, PhD, on patient responses to combo nivolumab + ipilimumab in 1st line RCC

video-image

Zarnie Lwin, MBBS, FRACP, speculates on future development of combo pembrolizumab + lenvatinib

video-image

Alexander Stratigos, MD, PhD, speculates on next steps in the development of cemiplimab in BCC

video-image

Petros Grivas, MD, PhD, on whether the results of TROPHY-U-01 justify a larger Phase III study

video-image

Petros Grivas, MD, PhD, summarizes the clinical progress made in prostate cancer from ESMO 2020

video-image

Aditya Bardia, MD, MPH, describes the outcomes from the Phase III ASCENT study from ESMO 2020

video-image

Petros Grivas, MD, PhD, offers perspective on the JAVELIN Bladder 100 trial updated at ESMO 2020

video-image

Laurence Albigès, MD, PhD, offers opinion on whether CheckMate 214 is practice-changing

video-image

Alexander Stratigos, MD, PhD, provides perspective on the PD-1 biomarker in BCC

video-image

Jaffer Ajani, MD, shares thoughts on the CheckMate 577 study presented at ESMO 2020

video-image

Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020

video-image

Alexander Stratigos, MD, PhD, on the latest data investigating the use of cemiplimab in BCC

video-image

Petros Grivas, MD, PhD, offers thoughts on the TROPHY-U-01 clinical study from ESMO 2020

video-image

Petros Grivas, MD, PhD, discusses the COVID-19 and Cancer Consortium (CCC19) from ESMO 2020

video-image

Aditya Bardia, MD, MPH, discusses the design of newly approved sacituzumab govitecan